The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT02710747

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02710747
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02710747. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
Acronym
POWAT
Condition
Heart Valve Disease
Condition
Older Than 18-years-old
Condition
Without Any Liver or Kidney Diseases
Intervention (Genetic)
CYP2C9;VKORC1
Lead sponsor
Guangdong Provincial People's Hospital (class: other)

Record details

Record id
cardio:ct-nct02710747
Content hash
25e1323dbb44a98ef26fc1375db2726420322e98e9c66cffa092f66d19d66be5